{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28"}]}],"title":"TEAE - All, regardless of causality"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23"}]}],"title":"TEAE - Possibly related to study drug"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}],"title":"SAE - All, regardless of causality"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"SAE - Possibly related to study drug"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Discontinuations Due to SAEs (including death)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Discontinuations - Possibly related to study drug"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Discontinuations Due to Nonserious AEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Deaths - On Study"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Deaths - Possibly related to study drug"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Deaths - Within 30 days of Study Discontinuation"}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"Any untoward medical occurrence in a patient who received study drug was considered an adverse event (AE), without regard to possibility of causal relationship. Treatment-emergent adverse events (TEAE): those which occurred or worsened after baseline. An adverse event resulting in any of the following outcomes, or deemed to be significant for any other reason, was considered to be a serious adverse event (SAE): death; initial or prolonged inpatient hospitalization; a life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.","groups":[{"description":"Pemetrexed 500 mg/m2 intravenous (IV) every 21 days for 6 cycles","id":"OG000","title":"Pemetrexed"}],"paramType":"NUMBER","populationDescription":"Patients who received at least one dose of study drug.","reportingStatus":"POSTED","timeFrame":"baseline, up to 18 weeks","title":"Overview of Adverse Events","type":"PRIMARY","unitOfMeasure":"participants"}